The once-daily drug zilurgisertib, branded as Atebrioz, is approved for patients aged 12 years and older with fibrodysplasia ossificans. ..
GrowthPakistan brings you the latest news to keep an eye on Pakistan’s startup ecosystem. Business keeps you growing when you stay aware of your competitors' moves. GrowthPakistan offers Business, Tech, Global Tech, Global, Auto, and Startup News straight from industries all around the globe. This platform will help you identify upcoming opportunities not only in Pakistan but worldwide.
Email : growthpakistan@gmail.com
Whatsapp : +92320-9497079
© growthpakistan